In this episode, Martin reacts to an FDA advisory committee meeting involving Capricor Therapeutics, sharing his perspective on the discussion, the evidence presented, and the committee's deliberations. He examines the clinical data, regulatory considerations, and potential implications for the company's development program and investment outlook.

In this episode, Martin explains his approach to position sizing and portfolio allocation, discussing the mathematical principles he believes can improve long-term investment performance. He explores risk management, probability, expected returns, and capital preservation, illustrating how trade size can influence overall portfolio outcomes while sharing his perspective on balancing conviction with risk.

In this episode, Martin discusses his outlook for South Korea and the factors he believes could influence the country's market and technology sector. He also explains why he thinks investors often overestimate their edge, outlines his bullish thesis on SK Hynix, and revisits Capricor Therapeutics, sharing his perspective on the company's recent developments and investment outlook.

In this episode, Martin discusses whether the memory semiconductor industry may be approaching the peak of its current market cycle. He examines supply and demand trends, pricing dynamics, industry competition, and valuation across memory companies, explaining the factors he believes could determine whether the sector continues to strengthen or begins to weaken.

In this episode, Martin discusses why he has become more cautious on SanDisk and explains the factors shaping his outlook for the company. He also reviews Jazz Pharmaceuticals, examines Sun Pharmaceutical Industries and Samsung Biologics, and analyzes Kioxia, sharing his perspective on each company's business, competitive position, valuation, and potential opportunities and risks.

In this episode, Martin discusses recent developments involving Capricor Therapeutics and shares his perspective on the company's disclosures and outlook. He also revisits his bearish thesis on AMD, analyzes Tyra Biosciences, explains why he is constructive on Sarepta, and discusses TENX, examining each company's business, valuation, competitive position, and the factors he believes could influence their future performance.

In this archive lesson, Martin discusses investing and financial analysis, explaining key concepts related to evaluating businesses, interpreting market behavior, and making investment decisions. He shares his perspective on valuation, risk management, and portfolio strategy while answering questions and illustrating the reasoning behind his approach to investing.

In this archive clip, Martin debates an 18-year-old participant about the pharmaceutical price increase that brought him widespread public attention. The discussion explores the reasoning behind the pricing decision, differing views on drug pricing and healthcare economics, and the ethical and business arguments raised by both sides during the exchange.

In this episode, Martin discusses Capricor Therapeutics and shares his perspective on the company's patient data and related public statements. He examines the clinical results, trial design, and regulatory considerations, explaining the factors that shape his investment outlook and why he questions aspects of the company's interpretation of the data.

In this episode, Martin discusses the investing approach of Steve Cohen and the characteristics he believes contribute to long-term trading success. He also shares his perspective on managing drawdowns, controlling risk during periods of underperformance, and developing exit strategies for short positions, explaining the principles he believes are important for disciplined portfolio management.